News
Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the first interim analysis of the ALTA-1L study in terms of progression-free survival and improvement in health-related quality of life in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. The second interim analysis results published in 2020 confirm these primary findings.
Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in…
Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated, among…
Trazodone in the Treatment of Depressive Disorder – A Case Study
Presented by MUDr. Sylva Racková, Ph.D. Psychiatric Clinic, Plzeň
Hydrotherapy in the Treatment of Non-Healing Wounds
For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care…
Invasive Pulmonary Aspergillosis – A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19
Findings based on a literature review conducted and published in September 2020 show the occurrence…
Trifluridine/Tipiracil in the 3rd Line Treatment of mCRC − Case Study
The following case study describes the treatment of a patient with metastatic colorectal cancer…
Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma
In mid-2020, the European Commission approved two new fixed combinations of drugs by Novartis for…